NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

UK Bioscience Forum
London 7 October 2014
http://www.ukbioscienceforum.org/programme2014/
14:45 - 15:30

Early Access as part of a development strategy – the rationale, challenges and options available

Around the world, countless patients with a high degree of unmet medical needs are in urgent need of new therapeutic alternatives. Regulators, physicians and patients are actively seeking access to novel chemical entities still development by pharmaceutical and biotech companies. Within the UK, the MHRA has recently launch the UK Early Access to Medicines Scheme (EAMs) highlighting the recognised need to make new treatments available to patients as early as possible.

Greater awareness of the programs that allow early access to medicines meeting unmet medical need and how they work is essential for all stakeholders. Similarly, an understanding of when these programs can and cannot be used (and why), along with the potential risks and benefits is critical.

This presentation will provide an overview of the subject of early access, why it should be considered as part of any development strategy and one company GW Pharmaceuticals experience within this area.


Speakers
Mark Corbett
Senior Vice President, Clinigen Global Access Programs (GAP), Clinigen

Dr Geoffrey Guy
Chairman, GW Pharmaceuticals

Since DCVax-L is the first to receive PIM under EAMS .... I suspect it might get some attention during this part of the programme.

Here too:
European Biotech Week
http://www.biotechweek.org/about/
The European Biotech Week takes place annually during the first week of October. This year you can join us, either by partaking in, or organising an event any time from 6th to 12th of October.